13F Holdings
中文EN

KYNB KYNTRA BIO, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 921299 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY104.5%
TTM net income YoY-108.0%
TTM EPS YoY-108.0%
Revenue 3-yr CAGR-67.5%
Net income 3-yr CAGR—

Margins

Gross margin5.6%
Operating margin-1,089.4%
Net margin-326.0%
FCF margin-913.7%
EBITDA margin-1,089.4%

Returns

ROE—
ROA-18.6%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets114.7%
Debt / equity—
Current ratio1.16x
Interest coverage-6.53x

Cash quality & payout

Operating cash flow / net income2.80x
Accruals ratio33.5%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$6.44M$29.62M$46.80M$140.73M$235.31M
Cost of revenue$556,000$15.56M$3.96M$20.28M$12.87M
Gross profit$5.88M$14.06M$42.84M$120.45M$222.44M
R&D expense$23.52M$95.69M$266.47M$296.79M$387.04M
SG&A expense$27.71M$49.33M$86.48M$124.69M$123.92M
Operating income-$45.90M-$150.42M-$322.72M-$301.02M-$288.53M
Interest expense$8.76M$8.25M$8.10M$1.44M$1.07M
Pretax income-$58.29M-$153.37M-$323.22M-$294.87M-$290.68M
Income tax-$90,000-$269,000-$252,000$358,000$347,000
Net income$183.45M-$47.58M-$284.23M-$293.65M-$290.02M
EBITDA-$45.18M-$147.76M-$313.20M-$291.01M-$278.36M
EPS (basic)45.37-11.89-2.92-3.14-3.14
EPS (diluted)45.37-11.89-2.92-3.14-3.14
Weighted avg. shares (diluted)4.04M4.00M97.30M93.58M92.35M
Balance sheet
Cash & equivalents$47.87M$50.48M$81.55M$155.70M$171.22M
Short-term investments$41.11M$0$121.90M$266.31M$233.97M
Receivables$216,000$481,000$5.12M$16.30M$17.40M
Inventory$3.74M$3.15M$17.17M$40.44M$31.02M
Current assets$99.07M$196.51M$331.56M$492.83M$474.06M
PP&E, net—$0$4.79M$20.61M$28.28M
Total assets$119.59M$214.53M$423.53M$610.09M$773.82M
Current liabilities$29.24M$133.31M$217.67M$273.56M$225.50M
Total liabilities$115.12M$398.16M$585.73M$611.57M$544.71M
Shareholders' equity-$30.04M-$225.60M-$204.17M-$21.45M$209.15M
Shares outstanding4.05M4.04M98.77M94.17M92.88M
Cash flow statement
Operating cash flow-$4.77M-$138.00M-$315.02M-$145.93M-$82.23M
Capital expenditure$38,000$266,000$2.52M$3.74M$5.19M
Free cash flow-$4.81M-$138.26M-$317.54M-$149.67M-$87.42M
Investing cash flow$35.42M$125.99M$153.66M$89.12M-$426.97M
Financing cash flow-$86.03M-$255,000$122.75M$46.78M-$563,000
Depreciation & amortization$713,000$2.65M$9.52M$10.02M$10.17M
Stock-based compensation$6.58M$25.21M$50.77M$65.60M$71.16M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.